Recro Pharma Inc., of Malvern, Pa., disclosed a clinical strategy update following findings from a prespecified interim analysis conducted on the initial half of patients who completed enrollment in the company's REC-13-012 trial testing intranasal dexmedetomidine, Dex-IN, in the treatment of acute postoperative pain following bunionectomy surgery on post-op day zero.